Koopman Karen, Gaal Jose, de Krijger Ronald R
Martini Hospital, 9728 NT Groningen, The Netherlands.
Department of Pathology, Isala Hospital, 8025AB Zwolle, The Netherlands.
Cancers (Basel). 2019 Jul 29;11(8):1070. doi: 10.3390/cancers11081070.
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors that arise in the adrenal medulla and in extra-adrenal locations, such as the head, neck, thorax, abdomen, and pelvis. Classification of these tumors into those with or without metastatic potential on the basis of gross or microscopic features is challenging. Recent insights and scoring systems have attempted to develop solutions for this, as described in the latest World Health Organization (WHO) edition on endocrine tumor pathology. PCC and PGL are amongst the tumors most frequently accompanied by germline mutations. More than 20 genes are responsible for a hereditary background in up to 40% of these tumors; somatic mutations in the same and several additional genes form the basis for another 30%. However, this does not allow for a complete understanding of the pathogenesis or targeted treatment of PCC and PGL, for which surgery is the primary treatment and for which metastasis is associated with poor outcome. This review describes recent insights into the cell of origin of these tumors, the latest developments with regard to the genetic background, and the current status of tumor classification including proposed scoring systems.
嗜铬细胞瘤(PCC)和副神经节瘤(PGL)是罕见的神经内分泌肿瘤,起源于肾上腺髓质以及肾上腺外部位,如头、颈、胸、腹和盆腔。基于大体或微观特征将这些肿瘤分为有或无转移潜能的肿瘤具有挑战性。如世界卫生组织(WHO)最新版内分泌肿瘤病理学所述,最近的见解和评分系统试图为此开发解决方案。PCC和PGL是最常伴有胚系突变的肿瘤之一。超过20个基因导致高达40%的这些肿瘤具有遗传背景;相同及其他几个基因中的体细胞突变构成另外30%的基础。然而,这并不足以完全理解PCC和PGL的发病机制或靶向治疗,手术是其主要治疗方法,转移与不良预后相关。本综述描述了对这些肿瘤起源细胞的最新见解、遗传背景的最新进展以及肿瘤分类的现状,包括提议的评分系统。